Susan Ostmo None;
Thiago Barros de Oliveira None;
Aaron Coyner Boston AI Lab, Code R (Recipient);
Rebekah Gensure None;
Brittni Scruggs None;
Jamie Anderson None;
Darius Moshfeghi Akceso Advisors AG, Bayer, Congruence Medical Solutions, Ocular Surgery News, Praxis Inc, Retina Technologies LLC, Retina Today/Pentavision, Regeneron Pharmaceuticals, and SLACK, Akebia, Alcon, Allegro, Iconic Therapeutics, Irenix, Novartis, Pykus, and Visunex; having equity in DSentz, Grand Legend Technology, Linc, Pr3vent, Promisight, Pykus, VersI, and Visunex; serving on the board of directors for DSentz, Linc, Pr3vent, and Promisight, Code C (Consultant/Contractor), Akebia Therapeutics, Bayer, Novartis, Regeneron Pharmaceuticals, and the Shapiro Law Group, Code F (Financial Support), Aldeyra Therapeutics, Apellis, Genentech, the National Institutes of Health, and Regeneron Pharmaceuticals, Code R (Recipient), CMEOutfitters.com, Cole Eye Institute, Northwell Health, Prime Medical Education, Regeneron Pharmaceuticals, University of Miami, Vindico, and Visunex, Code S (non-remunerative);
J. Peter Campbell Boston AI Lab, Code C (Consultant/Contractor), Genentech, Code F (Financial Support), Siloam Vision, Code O (Owner), Boston AI Lab, Code R (Recipient)